Raji Sundaramoorthi
Publications by Year
Research Areas
Protein Kinase Regulation and GTPase Signaling, Chronic Myeloid Leukemia Treatments, Protein Tyrosine Phosphatases, Bone health and treatments, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance(2009)1,234 cited
- → Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant(2010)358 cited
- Expression and isolation of antimicrobial small molecules from soil DNA libraries.(2001)
- → Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML(2004)198 cited
- → Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity(2000)133 cited
- → Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance(2006)108 cited
- → Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine‐based Compounds(2005)86 cited
- → AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes(2005)79 cited
- → In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit(2005)61 cited
- → Src Homology-2 Inhibitors: Peptidomimetic and Nonpeptide(2002)58 cited